echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Diabetes: Enpagliflozin treatment improves heart energy and function in patients with type 2 diabetes by reducing the volume of cardiomyocytes

    Diabetes: Enpagliflozin treatment improves heart energy and function in patients with type 2 diabetes by reducing the volume of cardiomyocytes

    • Last Update: 2021-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cardiovascular disease is the main cause of morbidity and mortality in patients with type 2 diabetes


    Heart failure (HF) is the first manifestation of the most common cardiovascular disease in T2D.


    All scans were performed on a 3.


    Therefore, using cardiovascular magnetic resonance imaging (CMR) and 31 phosphate magnetic resonance spectroscopy (31P-MRS), to explore the effect of selective SGLT2i empagliflozin on myocardial energetics, cell volume, function and perfusion


    Results: Enpagliflozin treatment significantly improved the PCr/ATP ratio (1.


    Table 1 Changes of clinical parameters after empagliflozin treatment

    Table 1 Changes of clinical parameters after empagliflozin treatment

    Table 2 Changes in CMR results after empagliflozin treatment

    Table 2 Changes in CMR results after empagliflozin treatment

    Figure 1 Comparison of the ratio of myocardial creatine phosphate to ATP (PCr/ATP) between patients with type 2 diabetes and the control group at baseline and the change of PCr/ATP before and after 12 weeks of treatment with empagliflozin


    Figure 1 Comparison of the ratio of myocardial creatine phosphate to ATP (PCr/ATP) between patients with type 2 diabetes and the control group at baseline and the change of PCr/ATP before and after 12 weeks of treatment with empagliflozin


    Figure 2 compares the left ventricular ejection fraction (LVEF) of patients with type 2 diabetes and the control group under the basal state, and the changes of left ventricular ejection fraction (LVEF) before and after 12 weeks of treatment


    Figure 2 compares the left ventricular ejection fraction (LVEF) of patients with type 2 diabetes and the control group under the basal state, and the changes of left ventricular ejection fraction (LVEF) before and after 12 weeks of treatment


    Enpagliflozin improves the state of "heart energy insufficiency", reverses the unfavorable myocardial cell remodeling, and improves heart function, providing a therapeutic opportunity for the prevention or treatment of heart failure in T2D

    Original source:

    Thirunavukarasu S, Jex N, Chowdhary A,et al.


    Empagliflozin Treatment is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.